Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Triphasil is a combination oral contraceptive (birth control pill) containing two synthetic hormones—levonorgestrel (a progestin) and ethinyl estradiol (an estrogen)—administered in a triphasic regimen. It primarily prevents pregnancy by suppressing ovulation through inhibition of gonadotropin secretion. Additional contraceptive effects include thickening of cervical mucus to hinder sperm penetration and altering the endometrial lining to reduce the likelihood of implantation. Each 28-day cycle consists of three phases with varying hormone doses, followed by seven inert tablets. The product does not protect against sexually transmitted infections. The brand has been discontinued in the U.S., but generic equivalents may be available[1][3][4][5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Triphasil.